Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.55 |
| ▸ | SYK | P43405 | 11/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | BCR | P11274 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22347706 | 1.00 | CNR1 (0.55) | CNR1SYKEGFRPIK3CGPIK3CA | |
| SCHEMBL29814227 | 0.84 | CDK2 (0.51) | SYKEGFRPIK3CGPIK3CAPIK3CB | |
| SCHEMBL20377616 | 0.84 | SYK (0.77) | SYK | |
| SCHEMBL28659402 | 0.82 | CNR1 (0.57) | CNR1SYK | |
| SCHEMBL27692103 | 0.81 | SYK (0.69) | SYKEGFRPIK3CGPIK3CAPIK3CB | |
| SCHEMBL27115445 | 0.79 | PIK3CG (0.66) | SYKPIK3CGPIK3CAPIK3CBCDK5 | |
| SCHEMBL27115896 | 0.78 | PIK3CG (0.76) | SYKEGFRPIK3CGPIK3CAPIK3CB | |
| SCHEMBL5733563 | 0.77 | MAPT (0.72) | PIK3CGPIK3CAPIK3CBCDK5ABL1 | |
| SCHEMBL27116528 | 0.77 | PIK3CG (0.64) | PIK3CGPIK3CAPIK3CBCDK5FLT3 | |
| SCHEMBL30626327 | 0.77 | LOX (0.55) | CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12227496-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12227496-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | CNR1 184/4885SYK 2508/4885EGFR 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.